

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

Medtech FAM Fund

A SUB-FUND OF FAM SERIES UCITS ICAV

CLASS J ACC - EUR ACCUMULATING ISIN: IE000J261N27

INVESTMENT MANAGER : CPR ASSET MANAGEMENT

MANAGEMENT COMPANY : FINECO ASSET MANAGEMENT DAC, WHICH IS PART OF FINECOBANK GROUP

Objectives and Investment Policy


The investment objective of the Sub-Fund is to provide capital appreciation over the long term. The Sub-Fund seeks to achieve its objective by investing in a diversified portfolio of global equity securities of companies involved in the medical technology ecosystem that can demonstrate their ability to comply with international sectoral standards for ESG. In actively managing the Sub-Fund, the Investment Manager will invest at least 75% of its net assets in equity and equity-linked securities of any country, without constraints of capitalization. Among this proportion of 75% of its assets, the Sub-Fund may invest in China A shares via Stock Connect within a maximum of 25% of its assets. The Sub-Fund may use derivatives for hedging, investment purposes and/or efficient portfolio management. The Sub-Fund is actively managed. There can be no guarantee that the investment objective will actually be attained. Investors can redeem their Shares on any Business Day, as defined in the supplement. Investors can ask for full or partial redemption of the Shares held. **SFDR Classification** : The Sub-Fund is classified as an Article 8 financial product under SFDR. For more detailed information on the ESG components of the Sub-Fund as well as the integration of sustainability risks into the investment decision process, please refer to the supplement and to the ICAV prospectus. **Benchmark Information** : The Investment Manager has selected the MSCI World Health Care Equipment and Supplies 10/40 Index NR ("Index") that will be used as a comparison for the investment performance only. The Investment Manager does not intend to replicate the composition of such Index and may at all times exercise total freedom by investing in securities which are not included in the referenced Index or which are present in different proportions.

Recommended for retail investors

- With a basic knowledge of investing in funds and no or limited experience of investing in the Sub-Fund or similar funds.
- Who understand the risk of losing some or all of the capital invested.
- Who are seeking capital growth and who are willing to accept a high level of volatility
- This fund may not be appropriate for investors who plan to withdraw their money within 5 years

This is a non-distributing unit class. Investment income is re-invested. Investors may sell on demand on any business day in Luxembourg.

Risk and Reward Profile



Additional key risks

The risk indicator reflects market conditions of recent years and may not adequately capture the following additional key risks of the Sub-Fund:

- **Operational risk:** Losses may occur due to human error or omission, process errors, system disruptions or external events.
- **Derivatives risk:** Derivatives create leverage in the Sub-Fund and may cause movements in the value of the underlying investments to amplify gains or losses to the Sub-Fund.
- **Counterparty Risk:** Losses may occur due to the failure of derivative counterparties to the Sub-Fund and where collateral arrangements are insufficient to cover the risk.
- **Liquidity Risk:** Losses may occur if adverse market conditions affect the ability to sell assets at a certain time and for a reasonable price.

What does this risk indicator mean?

The above risk indicator ranks potential risk and reward and is based on medium-term volatility (how sharply the Sub-Fund's actual or estimated unit price has gone up and down over five years). Historical data, such as that used in calculating this synthetic indicator, may not be a reliable indication of the future risk profile of the Sub-Fund. The lowest category does not mean a 'risk-free' investment. The Sub-Fund's risk indicator is not guaranteed and may change over time. For un-hedged currency classes, exchange rate movements may affect the risk indicator where the currency of the underlying investments differs from the currency of the unit class.

Charges

These charges cover the costs of running the Fund, including the costs of marketing and distributing it, and they reduce the potential growth of your investment.


One-off charges taken before or after you invest		
Entry charge	None	Maximum charges that might be taken out of your money before it is invested or before the proceeds of your investment are paid out.
Exit charge	None	
Charges taken from the Fund over a year		
Ongoing charges	1.18%	The ongoing charge is based on expenses for the period/year ending 31 December 2023.
Charges taken from the Fund under certain conditions		
Performance fee	None	

- **For entry and exit charges** you may pay less than the maximum amounts shown. Please consult your financial advisor or distributor.
- **Ongoing charges** vary from year to year. They do not include portfolio transaction costs and performance fees. The Fund’s annual report for each financial year will include details of the exact charges made at the Sub-Fund level.

For more information about charges, please consult the Prospectus of FAM Series UCITS ICAV, available at www.finecoassetmanagement.com

Past Performance

The performance of the Sub-Fund (in EUR) shown below, takes into account all ongoing charges, but no entry or exit charges. Past performance is not a reliable indicator of future performance.



Medtech FAM Fund

Benchmark: MSCI World Health Care Equipment and Supplies 10/40 Index NR

Fund inception: 2021

Share class launch: 2021

Practical Information

- **Depository** BNP Paribas Securities Services, Dublin Branch
- **Further information** Copies of the English Prospectus of FAM Series UCITS ICAV, the latest annual and semi-annual reports, details of the remuneration policy of the Management Company, the latest share prices as well as other practical information such as the key investor information documents (in English and in Italian) can be obtained free of charge upon request from the registered office of the Management Company and online at: www.finecoassetmanagement.com.
- **Taxation** The Fund is subject to the tax laws and regulations of Ireland. Depending on your country of residence, the tax legislation of Ireland may have an impact on your personal tax position.
- **Responsibility for information** The Management Company, Fineco Asset Management DAC, may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the ICAV’s Prospectus.
- **Fund structure** The Fund is a sub-fund of FAM SERIES UCITS ICAV, which is an Irish Collective Asset-management Vehicle with a range of sub-funds. The assets and liabilities of each sub-fund are segregated by law from those of other sub-funds. The Prospectus and the annual and semi-annual reports of FAM SERIES UCITS ICAV are prepared for the entire range.
- **To place orders** Instructions on how to buy, convert or redeem shares are set out in the Prospectus. Shareholders may have the right to convert shares of this Fund into the same class of shares of another FAM SERIES UCITS ICAV sub-fund.
- **Authorisation** The FAM Series UCITS ICAV and Management Company are authorised and regulated in Ireland by the Central Bank of Ireland.
- **Registered office** Fineco Asset Management dac of 6th Floor, Block A, George’s Quay, Dublin 2, Ireland.
- **Date:** This Key Investor Information is accurate as at 19 February 2024.